HC Wainwright Has Bearish Outlook for TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at HC Wainwright decreased their FY2026 EPS estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.50) per share for the year, down from their previous estimate of ($1.34). HC Wainwright currently has a “Buy” rating and a $67.00 target price on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.75) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04).

A number of other research firms have also weighed in on TNGX. William Blair initiated coverage on Tango Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. Wall Street Zen downgraded Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Guggenheim boosted their price target on Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Zacks Research lowered Tango Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 27th. Finally, Stifel Nicolaus set a $55.00 price objective on Tango Therapeutics in a research note on Friday, October 23rd. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Tango Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $45.54.

Tango Therapeutics Stock Up 5.9%

Shares of TNGX stock opened at $25.73 on Thursday. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of -18.78 and a beta of 1.26. The company’s 50 day moving average is $23.42 and its 200 day moving average is $22.66. Tango Therapeutics has a 52-week low of $7.49 and a 52-week high of $34.39.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors have recently added to or reduced their stakes in TNGX. Bessemer Group Inc. raised its position in shares of Tango Therapeutics by 11.2% in the 3rd quarter. Bessemer Group Inc. now owns 393,824 shares of the company’s stock valued at $9,826,000 after purchasing an additional 39,618 shares during the last quarter. ACT Capital Partners L.P. acquired a new stake in Tango Therapeutics in the 3rd quarter worth approximately $150,000. Fisher Asset Management LLC grew its position in Tango Therapeutics by 84.8% during the 3rd quarter. Fisher Asset Management LLC now owns 1,068,505 shares of the company’s stock worth $26,659,000 after purchasing an additional 490,347 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Tango Therapeutics by 4.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock worth $336,000 after purchasing an additional 534 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Tango Therapeutics during the 3rd quarter worth approximately $215,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insiders Place Their Bets

In related news, insider Jessica Newcomb sold 7,031 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $22.42, for a total transaction of $157,635.02. Following the transaction, the insider directly owned 52,090 shares of the company’s stock, valued at $1,167,857.80. This represents a 11.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Adam Crystal sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $22.42, for a total value of $112,100.00. Following the transaction, the insider directly owned 115,743 shares in the company, valued at $2,594,958.06. This represents a 4.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 47,231 shares of company stock valued at $1,129,029 in the last three months. Insiders own 6.50% of the company’s stock.

Latest Tango Therapeutics News

These are some of the TNGX news items that stood out recently:

• Positive Sentiment: JPMorgan raised its price target to $47 from $46 and reiterated an “overweight” rating, signaling continued confidence in the stock. JPMorgan analyst update
• Positive Sentiment: TNGX was reported to have moved above its 50-day moving average despite a recent quarterly earnings miss, a potentially supportive technical signal. Stock moves above 50-day average
• Negative Sentiment: HC Wainwright cut its EPS estimates across 2026 and 2027, including its FY2027 loss estimate to $1.75 per share from $1.54. It also trimmed its price target to $67 from $68, although it kept a “buy” rating. The revisions suggest expectations for larger losses and may weigh on sentiment. HC Wainwright lowers expectations

Tango Therapeutics Company Profile

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.